Expert Panel to discuss COVID-19 Vaccination

Expert Panel to discuss COVID-19 Vaccination


Student getting vaccinated by medical professional

Misericordia University will be hosting a live virtual expert panel followed by a Q&A session on Tuesday, May 4, 2021 from 11 a.m. – 12 p.m to discuss COVID-19 vaccine protection with the goal of increasing vaccination rates and decreasing hesitancy.

A panel consisting of Mark Alles, former chairman & CEO of Celgene Corporation and current member of the Board of Directors for Antengene Corporation and Syros Pharmaceuticals, Allison Brodginsky, D.O., Director of Infectious Diseases, Geisinger Northeast, and Brenda Hage, PhD, DNP, CRNP, Professor of Nursing and DNP Program Director, Misericordia University, will discuss how we as individuals and communities are being affected by the vaccination process and how we can obtain the information we need to make healthy choices for ourselves and loved ones.

George Godlewski

The Webinar and Q & A session will be moderated by George Godlewski, MSW, Ph.D., Chair, Department of Health Science & Healthcare Analytics, Program Director, Healthcare Analytics, Misericordia University.

Additional topics to be discussed include: FDA processes that assure vaccine safety, the real extent of serious side effects, herd immunity, issues related to viral variants, and more.


Members of the Misericordia community are invited to register by visiting this link.  After registering, you will receive a confirmation email containing information about joining the webinar.  Live questions will also be taken during the webinar as time permits. This event will be recorded and eventually posted to the Misericordia website in the COVID-19 Updates & Protocols area.

For technical questions regarding the webinar please contact, George Godlewski, at .

Panelist Bios:

Dr. Brenda Hage

Brenda Hage, PhD, DNP, CRNP

Hage is a tenured professor of nursing with her primary teaching areas including advanced bioethics and public policy; informatics; leadership; and the scholarship of inquiry in the DNP programs. She is a family nurse practitioner with clinical expertise in gerontology, rehabilitation, and family practice. She serves as the associate medical director at a pro-bono community health clinic, The Hope Center, Luzerne, PA. Hage is board certified as a Family NP by the American Academy of Nurse Practitioners (NP-C), and as an Adult Gerontological Primary Care NP (AGPCNP-BC) and Informatics Nurse (R.N., B.C.) by the American Nurses Credentialing Corporation and Certified Case Manager (C.C.M.) by the Commission for Case Manager Certification.


Mark Alles

Mark Alles

Alles is an accomplished biopharmaceutical executive who was instrumental in building highly successful global oncology-focused organizations and cancer therapeutics over a more than three-decade career. He is the former Chairman and Chief Executive Officer of Celgene Corporation, a global biopharmaceutical company, with an outstanding record of driving growth and medical innovation throughout a 15 -year tenure at the company. He is a recognized industry leader with deep operational, financial, business development, and commercial experience. Alles is a former Board member of the Pharmaceutical Research and Manufacturers of America (PhRMA), the European Federation of Pharmaceutical Industries and Associations (EFPIA), the Biotechnology Innovation Organization (BIO), Gilda’s Club NYC (non-profit helping families of people living with cancer), and a former member of the Trustees for the Healthcare Institute of New Jersey (HINJ). He is currently a member of the Board of Directors for Antengene Corporation and Syros Pharmaceuticals.

Alles was appointed to Celgene’s Board of Directors in February 2016, Chief Executive Officer in March 2016, and was elected Chairman in February 2018. He consistently delivered industry-leading financial performance, led teams that completed several multibillion-dollar companies or asset acquisitions, built a diverse suite of globally marketed medicines and a pipeline of high-potential therapeutics for blood cancers, solid tumor cancers, and serious inflammatory diseases. Led the expansion of Celgene from a US-based organization with less than 500 employees, to a global company serving patients in more than 50 countries with 8,800 employees. He optimized long-term shareholder value through the analysis, execution, and completion of Bristol Myers Squibb’s $74B acquisition of Celgene Corporation in November 2019.

Previously, Alles served as Celgene’s President and Chief Operating Officer, Executive Vice President, and Global Head of Hematology & Oncology and was also Celgene’s Chief Commercial Officer. He joined Celgene in April 2004 as Vice President, Global Hematology Marketing. Before joining Celgene, Alles was Vice President of the U.S. Oncology business unit at Aventis Pharmaceuticals and served in other senior commercial management roles at Aventis (Rhône-Poulenc Rorer) over an eleven-year period. He began his career in the pharmaceutical industry at Bayer and worked at Centocor before its acquisition by Johnson & Johnson. Alles earned his B.S. degree from Lock Haven University of Pennsylvania and served as a Captain in the United States Marine Corps.

Allison Brodginsky, D.O.

Brodginski is the Northeast Director of Infectious Diseases and Associate Chief Medical Officer at Geisinger Wyoming Valley. She received her Doctor of Medicine degree from Lake Erie College of Medicine. She later completed her residency in internal medicine at New York Downtown Hospital/Weill Cornell Medical Center, where she also served as chief medical resident. Her Infectious Diseases fellowship was at The Mount Sinai Hospital in New York. Brodginski began at Geisinger in 2013 as an associate in Infectious Diseases in Geisinger Medical Center, Danville PA. She later transferred to Geisinger Wyoming Valley and became Northeast Director of Infectious Diseases. Now serves as the Chief Medical Officer of Geisinger Wyoming Valley, Geisinger System Director of Public Health Preparedness along with her Infectious Diseases role.

Her work at Geisinger is heavily integrated into Quality and Patient Safety. She is the chairman of the GWV Performance improvement Committee which coordinates all PI activities for all the clinical and ancillary departments, MOC tracers, Joint Commission and Dept of Health surveys, RCAs, action plans. She is also the Chair of GWV Ethics committee which provides review of ethics consults, educational programs, palliative care involvement and Schwarz Rounds. Her involvement in Infection Control leads to numerous Infection projects with proven success in decreasing hospital-acquired infections and updating the system isolation practices which significantly improved throughput. Most recently she accepted a Geisinger system position as Director of Public Health Preparedness as she has been involved with COVID-19 related system policies, treatment guidelines, patient isolation updates, and lead physician for employee health. In addition to work at the hospital, she also serves as a Clinical Associate Professor of Medicine at Geisinger Commonwealth School of Medicine. Her role at GCSOM functions as the Northeast Facilitator for Quality Improvement projects.


Source link